Optimization and validation of a spe-hplc-pda method using quantitative structure-retention relationship based on mapping the hydropathy for simultaneous determination of drugs

Autor: Carlucci, G, Palumbo, P, Carlucci, M, Milanetti, E, Olimpieri, Pp, Ferrone, V.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3983::09063e4248593ad35154defa629d9f6d
http://hdl.handle.net/11697/129348

The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.

Autor: Breccia M; Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Celant S; AIFA Italian Medicines Agency, Rome, Italy., Palandri F; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Passamonti F; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy., Olimpieri PP; AIFA Italian Medicines Agency, Rome, Italy., Summa V; AIFA Italian Medicines Agency, Rome, Italy., Guarcello A; AIFA Italian Medicines Agency, Rome, Italy., Palumbo GA; Hematology with BMT Unit, A.O.U. 'G. Rodolico-San Marco', Italy University of Catania, Catania, Italy., Pane F; Università Degli Studi di Napoli Federico II, Naples, Italy., Guglielmelli P; CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, DMSC, University of Florence, AOU Careggi, Florence, Italy., Corradini P; Università Degli Studi di Milano & Divisione Ematologia, Fondazione IRCCS Istituto Nazionale Dei Tumori di Milano, Milan, Italy., Russo P; AIFA Italian Medicines Agency, Rome, Italy.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Oct 03. Date of Electronic Publication: 2024 Oct 03.

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Autor: Iacovino ML; National Cancer Institute, IRCCS Fondazione G.Pascale, Naples, Italy., Celant S; Italian Medicines Agency, Rome, Italy., Tomassini L; Italian Medicines Agency, Rome, Italy., Arenare L; National Cancer Institute, IRCCS Fondazione G.Pascale, Naples, Italy., Caglio A; Department of Oncology, University, Ordine Mauriziano Hospital Umberto I, Turin, Italy., Canciello A; National Cancer Institute, IRCCS Fondazione G.Pascale, Naples, Italy., Salerno F; Department of Oncology, University, Ordine Mauriziano Hospital Umberto I, Turin, Italy., Olimpieri PP; Italian Medicines Agency, Rome, Italy., Di Segni S; Italian Medicines Agency, Rome, Italy., Sferrazza A; Italian Medicines Agency, Rome, Italy., Piccirillo MC; National Cancer Institute, IRCCS Fondazione G.Pascale, Naples, Italy., Domenico Beretta G; Medical Oncology, Hospital, Pescara, Italy., Pinto C; Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Italy., Blasi L; Medical Oncology, Civic Hospital Cristina Benfratelli, Palermo, Italy., Cinieri S; Medical Oncology and Breast Unit, Perrino Hospital, Brindisi, Italy., Cavanna L; Medical Oncology and Hematology, Civil Hospital, Piacenza, Italy., Di Maio M; Department of Oncology, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, Italy., Russo P; Italian Medicines Agency, Rome, Italy., Perrone F; National Cancer Institute, IRCCS Fondazione G.Pascale, Naples, Italy.

Publikováno v: The Lancet regional health. Europe [Lancet Reg Health Eur] 2024 Jun 24; Vol. 42, pp. 100973. Date of Electronic Publication: 2024 Jun 24 (Print Publication: 2024).

Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.

Autor: Arca M; Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy., Celant S; Italian Medicines Agency Rome Italy., Olimpieri PP; Italian Medicines Agency Rome Italy., Colatrella A; Italian Medicines Agency Rome Italy., Tomassini L; Italian Medicines Agency Rome Italy., D'Erasmo L; Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy., Averna M; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) University of Palermo Palermo Italy., Zambon A; Department of Medicine-DIMED University of Padua Italy., Catapano AL; Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti University of Milan and IRCCS Multimedica Milan Italy., Russo P; Italian Medicines Agency Rome Italy.

Publikováno v: Journal of the American Heart Association [J Am Heart Assoc] 2023 Nov 07; Vol. 12 (21), pp. e026550. Date of Electronic Publication: 2023 Oct 18.

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.

Autor: Torti C; Department of Medical and Surgical Sciences, 'Magna Graecia' University, Catanzaro, Italy., Olimpieri PP; Italian Medicines Agency, Via del Tritone 181, 00187 Rome, Italy.; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy., Bonfanti P; Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy., Tascini C; Department of Medicine (DAME), Infectious Diseases Clinic, Udine University Hospital, Udine, Italy., Celant S; Italian Medicines Agency, Via del Tritone 181, 00187 Rome, Italy., Tacconi D; Department of Specialised and Internal Medicine, Infectious Diseases Unit, San Donato Hospital, Arezzo, Italy., Nicastri E; National Institute for Infectious Disease Lazzaron Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy., Tacconelli E; Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, 37129 Verona, Italy., Cacopardo B; Department of Internal and Experimental Medicine, University of Catania School of Medicine, Catania, Italy., Perrella A; Division Emerging Infectious Disease and High Contagiousness, D. Cotugno Hospital, 80131 Naples, Italy., Buccoliero GB; Infectious Diseases Unit, San Giuseppe Moscati Hospital, Azienda Sanitaria Locale Taranto, 74121 Taranto, Italy., Parruti G; Department of Medicine, Infectious Disease Unit, Pescara General Hospital, Pescara, Italy., Bassetti M; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.; Infectious Diseases Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy., Biagetti C; Unit of Infectious disease Infermi Hospital, AUSL Romagna, Rimini, Italy., Giacometti A; Azienda Ospedaliera Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy., Erne EM; Department of Infectious Disease, Azienda Sanitaria dell'Alto Adige, Central Hospital of Bolzano, Italy., Frontuto M; Infectious Diseases Unit, A.O.R. San Carlo, Potenza, Italy., Lanzafame M; Department of Medical, Infectious Diseases Unit, Santa Chiara Hospital, Trento, Italy., Summa V; Italian Medicines Agency, Via del Tritone 181, 00187 Rome, Italy., Spagnoli A; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy., Vestri A; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy., Di Perri G; Department of Medical Sciences at the Unit of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Torino, Italy., Russo P; Italian Medicines Agency, Via del Tritone 181, 00187 Rome, Italy., Palù G; Italian Medicines Agency, Via del Tritone 181, 00187 Rome, Italy.

Publikováno v: The Lancet regional health. Europe [Lancet Reg Health Eur] 2023 Jul 14; Vol. 31, pp. 100684. Date of Electronic Publication: 2023 Jul 14 (Print Publication: 2023).